Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis
Year: 2024
Type: article
Study design: Observational Study
Abstract: • Four years secukinumab retention rates were rather high, approximatively 50% in axSpA and PsA patients, which is comparable to previously reported TNFi retention rates. • Four years secukinumab retention and remission rates were higher in bio-naïve patients compared to patients with prior b/tsDMARD exposure, particularly in axSpA. • Based on data from more than 1500 European patients with axSpA or PsA, the generalizability of our results is high. In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according to disease activity measures and patient-reported outcomes at 24 and 48 months. Data on patients with axSpA and PsA who initiated secukinumab treatment were pooled from 13 European registries. Analyses were performed overall and stratified according to the number of previous biologic/targeted synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs, 0/1/≥ 2). Kaplan-Meier plots and Cox regression analyses were performed to assess and compare secukinumab retention rates. Comparisons of remission and LDA rates were performed by logistic regression analyses. The overall 24-/48-month secukinumab retention rates were 61%/51% in 767 axSpA patients, and 64%/49% in 975 PsA patients, respectively. Compared to b/tsDMARD naïve patients, a higher risk of withdrawal from secukinumab was found for those with ≥ 2 prior b/tsDMARDs in axSpA and PsA, and 1 prior b/tsDMARD in axSpA. Generally, remission and LDA rates were numerically higher in b/tsDMARD naïve patients. After adjustment for confounders, statistically significantly higher remission and LDA rates were found for b/tsDMARD naïve patients compared to patients with ≥ 2 prior b/tsDMARDs at 24 months in axSpA and PsA. This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD naïve patients had higher retention, remission and LDA rates than patients with prior b/tsDMARD exposure.
Source: Joint Bone Spine
Authors: Marion Pons, Stylianos Georgiadis, Mikkel Østergaard, Zohra Faizy Ahmadzay, Bente Glintborg, Jette Heberg, Sara Nysom Christensen, Simon Rasmussen, Anne Gitte Loft, Isabel Castrejón, Fernando Sánchez-Alonso, Florenzo Iannone, Dan Nordström, Anna-Mari Hokkanen, Adrian Ciurea, Michael J. Nissen, Jakub Závada, Karel Pavelka, Ziga Rotar, Katja Perdan Pirkmajer, Brigitte Michelsen, Pawel Mielnik, Miguel Bernardes, Nikita Khmelinskii, Karin Laas, Sigrid Vorobjov, Catalin Codreanu, Gary J. Macfarlane, Gareth T. Jones, Bjorn Gudbjornsson, Olafur Palsson, Johan K. Wallman, Irene van der Horst-Bruinsma, Fatos Onen, Merete Lund Hetland, Lykke Midtbøll Ørnbjerg
Institutions: Glostrup Hospital, Rigshospitalet, University of Copenhagen, Aarhus University, Aarhus University Hospital, Universidad Complutense de Madrid, Hospital General Universitario Gregorio Marañón, University of Bari Aldo Moro, Helsinki University Hospital, University of Zurich, University Hospital Zurich, University Hospital of Geneva, Charles University, Institute of Rheumatology, University of Ljubljana, Ljubljana University Medical Centre, Diakonhjemmet Hospital, Sørlandet Sykehus, Helse Førde, Universidade do Porto, Hospital de São João, University of Lisbon, Instituto de Medicina Molecular João Lobo Antunes, Unidade Local de Saúde Santa Maria, East Tallinn Central Hospital, National Institute for Health Development, Carol Davila University of Medicine and Pharmacy, University of Aberdeen, University of Iceland, National University Hospital of Iceland, Lund University, Skåne University Hospital, Radboud University Medical Center, Dokuz Eylül University
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,020
Award: G3475100684
OpenAlex ID: W4404733946